Dr. Apar K. Ganti
Claim this profileUniversity of Nebraska Medical Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
8 reported clinical trials
15 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage I
Stage II
Stage IV
2Lung Cancer
Stage II
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Apar K. Ganti is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
More about Apar K. Ganti
Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Apar K. Ganti has experience with
- Pembrolizumab
- Carboplatin
- TAB004
- Toripalimab
- Crizotinib
- Capecitabine
Breakdown of trials Apar K. Ganti has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
Metastatic Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Apar K. Ganti specialize in?
Apar K. Ganti focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage I patients, or patients who are Stage II.
Is Apar K. Ganti currently recruiting for clinical trials?
Yes, Apar K. Ganti is currently recruiting for 5 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Apar K. Ganti has studied deeply?
Yes, Apar K. Ganti has studied treatments such as Pembrolizumab, Carboplatin, TAB004.
What is the best way to schedule an appointment with Apar K. Ganti?
Apply for one of the trials that Apar K. Ganti is conducting.
What is the office address of Apar K. Ganti?
The office of Apar K. Ganti is located at: University of Nebraska Medical Center, Omaha, Nebraska 68105 United States. This is the address for their practice at the University of Nebraska Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.